Filtered By:
Vaccination: Shingles (Herpes Zoster) Vaccine
This page shows you your search results in order of relevance. This is page number 18.
Order by Relevance | Date
Total 2010 results found since Jan 2013.
Capturing the value of vaccination: impact of vaccine-preventable disease on hospitalization
Aging Clin Exp Res. 2022 May 28. doi: 10.1007/s40520-022-02110-2. Online ahead of print.ABSTRACTEvidence from epidemiological studies suggests that vaccine-preventable disease (VPD) such as influenza or herpes zoster contribute significantly to the increased risk of older adults for cardiovascular, cerebrovascular, neurological, and renal complications in the period after illnesses. However, since the period of elevated risk can persist well beyond the duration of the acute illness, the connection is not always recognized. To obtain insights into the relationship between diagnoses for vaccine-preventable disease and for ot...
Source: Herpes - May 28, 2022 Category: Infectious Diseases Authors: Mark T Doherty Emmanuel Aris Nathalie Servotte Ekkehard Beck Source Type: research
Recombinant Zoster Vaccine Uptake and Risk of Flares Among Older Adults with Immune-Mediated Inflammatory Diseases in the United States
CONCLUSIONS: We did not find an increase in presumed flares following RZV vaccination. Among adults aged ≥50 years with IMIDs, a substantial proportion received RZV compared to general zoster coverage estimates and series-completion was high. This article is protected by copyright. All rights reserved.PMID:35666070 | DOI:10.1002/art.42261
Source: Herpes - June 6, 2022 Category: Infectious Diseases Authors: Jessica Leung Tara C Anderson Kathleen Dooling Fenglong Xie Jeffrey R Curtis Source Type: research
Safety and efficacy in the nursing care of people with rheumatic diseases on janus kinase inhibitor therapy
Rheumatol Int. 2022 Aug 18. doi: 10.1007/s00296-022-05185-2. Online ahead of print.ABSTRACTNurses's support of patients needs an evidence base as much as that of specialists management. However, some more practical aspects need specific questions that are not addressed in medical societies' recommendations. Our objective was to investigate the effect of Janus kinase inhibitors (jakinibs) on efficacy, safety, infections, cardiovascular risk, vaccination, pregnancy and lactation, interactions, surgery, and switch in adult patients with rheumatic diseases. We used the methodology for rapid reviews. Medline was searched for sy...
Source: Herpes - August 18, 2022 Category: Infectious Diseases Authors: Laura Lorena Castiblanco Mar ía Jesús García de Yébenes Jose Mar ía Martín Martín Loreto Carmona Source Type: research
STELARA ® (ustekinumab) Demonstrated Sustained Symptomatic and Corticosteroid-Free Remission Through Four Years in Adults with Moderately to Severely Active Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced final data from the long-term extension (LTE) of the Phase 3 UNIFI study demonstrating efficacy and safety of STELARA® (ustekinumab) through four years of treatment in adult patients with moderately to severely active ulcerative colitis (UC).1 Among all patients who had achieved clinical responsea with STELARA during induction, 64.9 percent were in symptomatic remissionb after 44 weeks of maintenance. At week 200 (four years), this proportion of patients was 55.2 percent; the majority (96.4 percen...
Source: Johnson and Johnson - October 10, 2022 Category: Pharmaceuticals Source Type: news
Factors associated with pneumococcal vaccine uptake among vulnerable older adults in the United States primary care setting
This study assessed factors associated with having gotten a pneumococcal vaccine among vulnerable adults aged 50 and older. This study used the 2018 Medical Expenditure Panel Survey nationally representative dataset. Eligible individuals were aged 50-64 with an 'at risk' health condition or ≥65 years and had a primary care provider as their usual source of care (N = 3,760). Binary logistic regression was used to test factors (identified from literature) for a significant association with getting the pneumococcal vaccine. Factors with significant associations were entered into an adjusted multivariable logistic regression...
Source: Vaccine - October 13, 2022 Category: Allergy & Immunology Authors: Megan Whaley David R Axon Source Type: research
Safety Surveillance of Varicella Vaccines in the Vaccine Adverse Event Reporting System, United States, 2006-2020
CONCLUSIONS: No new or unexpected safety findings were detected for VAR and MMRV given as recommended, reinforcing the favorable safety profiles of these vaccines. Providers should obtain specimens for viral testing and strain-typing for serious AEs if they consider vVZV as the possible causative agent.PMID:36265846 | DOI:10.1093/infdis/jiac306
Source: Herpes - October 20, 2022 Category: Infectious Diseases Authors: Pedro L Moro Jessica Leung Paige Marquez Yeowon Kim Shaokui Wei John R Su Mona Marin Source Type: research
Adult Vaccination
Am Fam Physician. 2022 Nov;106(5):534-542.ABSTRACTAdult vaccination rates are low in the United States, despite clear benefits for reducing morbidity and mortality. Vaccine science is evolving rapidly, and family physicians must maintain familiarity with the most recent guidelines. The recommended adult immunization schedule is updated annually by the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention. All eligible patients should receive SARS-CoV-2 vaccines according to the current guidelines. Adults without contraindications should also receive an annual influenza vaccine. Hepa...
Source: Herpes - November 15, 2022 Category: Infectious Diseases Authors: Grant M Greenberg Princy A Koshy Mary Jane S Hanson Source Type: research
Patterns of use of recombinant zoster vaccine among commercially-insured immunocompetent and immunocompromised adults 50-64 years old in the United States
CONCLUSIONS: RZV uptake was low in the two years since the CDC recommendation, and differed by demographic, healthcare access, and clinical characteristics. Initiation rates were higher among immunocompromised adults compared to immunocompetent adults, despite no CDC recommendation for vaccination in these groups during the study period. The CDC has since recommended RZV for immunocompromised individuals, and our findings may inform efforts to increase RZV uptake in individuals at higher risk of severe disease.PMID:36396511 | DOI:10.1016/j.vaccine.2022.10.076
Source: Vaccine - November 17, 2022 Category: Allergy & Immunology Authors: Jonathan Fix Nadja A Vielot Jennifer L Lund David J Weber Jennifer S Smith Michael G Hudgens Sylvia Becker-Dreps Source Type: research
